Figure 6

In vivo antitumor activity of epertinib in the breast cancer IVM. Epertinib inhibits the growth of breast cancer in animal models. In each animal model, vehicle or indicated doses of epertinib were orally administered daily. Tumor volume was measured twice or thrice weekly and the mean tumor volume with SD is represented by each data point. Human breast cancer cells, MDA-MB-361 (A) or MDA-MB-361-luc-BR2 (B) was implanted orthotopically into the mammary fat pad of mice. Tumor-bearing mice were treated for 28 days (A and B). Tumor growth in the breast cancer IVM (MDA-MB-361-luc-BR3) was monitored by the photons emitted from the tumor as an indicator, which was measured with an IVIS Imaging System 200 (Caliper Life Sciences). Tumor-bearing mice were orally administered vehicle or the 50 mg/kg doses of epertinib for 30 days. The photons were measured once or twice weekly and the mean photons/sec with SD are presented at each data point (n  =  3 for vehicle, n  =  4 for 50 mg/kg of epertinib) (C). Bioluminescent images at the last measurement *P  <  0.05, **P  <  0.01 (epertinib versus vehicle, Dunnet’s test) (D).